



**INTERNATIONAL JOURNAL OF
PHARMACEUTICAL SCIENCES**
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: <https://www.ijpsjournal.com>



Review Paper

Overview of Bioactive Phytochemicals in *Withania somnifera* Relieving Stress and Anxiety on Cum- Huntington Disease

Praveen Raja S*, Sri Dharshan K, Kalaivani D, Keerthana M

Faculty of Pharmacy, SBMCH Campus, BIHER (DU), Chennai, Tamil Nadu, India

ARTICLE INFO

Published: 21 Nov 2025

Keywords:

Withania somnifera
(Ashwagandha), anxiety,
Anti-inflammatory,
Huntington disease,
Phytochemicals.

DOI:

10.5281/zenodo.17672594

ABSTRACT

Withania somnifera, commonly known as Ashwagandha, is a revered adaptogenic herb in traditional Ayurvedic medicine, renowned for its ability to enhance the body's resilience to stress and anxiety. Modern scientific research has supported its potential role in alleviating symptoms of chronic stress and anxiety disorders. The active compounds in *Withania somnifera*, particularly withanolides, have been shown to regulate cortisol levels, the primary stress hormone, while also influencing neurotransmitters such as GABA, serotonin, and dopamine, which are critical in mood regulation. Clinical studies suggest that Ashwagandha supplementation can significantly reduce perceived stress, anxiety, and the physiological effects associated with chronic stress, such as increased heart rate and blood pressure. Furthermore, Ashwagandha's neuroprotective and anti-inflammatory properties may contribute to improving mental well-being by reducing oxidative stress, which is linked to mood disorders. Despite its promising effects, further research is needed to fully understand the mechanisms by which *Withania somnifera* exerts its therapeutic effects on stress and anxiety. However, the current evidence supports its potential as a natural, adjunctive treatment for individuals seeking to manage stress and anxiety more effectively.

INTRODUCTION

The presence of high-value secondary metabolites in plant-based bio actives, which offer health advantages, has researchers increasingly interested these days. Given the state of global healthcare today, more than 80% of the global populace, especially in developing nations that rely on phytomedicines for their medicinal requirements

(1). The continued success of conventional systems of treatments like Ayurveda, Chinese medicine, and Greco-Arab (UnaniTibb) techniques is because that phytomedicines are less harmful and are cost-effective (2-4). It is widely acknowledged that plants of the Solanaceae family's genus *Withania* are essential for medicine because of their high therapeutic and nutraceutical

***Corresponding Author:** Praveen Raja S

Address: Faculty of Pharmacy, SBMCH Campus, BIHER (DU), Chennai, Tamil Nadu, India

Email ✉: praveenraja1514@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.



possible. One of the genus's plants, *W. somnifera*. (Figure 1), which had numerous medical uses together with pharmaceutical uses. *W. somnifera*, sometimes known as Winter cherry, Indian ginseng, suranjan, in Africa. Pakistan, India, Sri Lanka, and the Mediterranean (5–9). In the medicinal system of Ayurveda, roots and Plant leaves were thought to be phytotherapeutic drugs to treat a variety of illnesses. Different clinical and Preclinical studies showed that the herb could cure neurological conditions (11) hepatotoxicity (10), and anxiety Parkinson's disease (13).

Huntington disease (12) (2, 14). Significant levels were present in the fruits of saponins and the leaves. Withanolides, pharmacologically active steroidal lactones, were found in *W. somnifera* through phytochemical study (16, 17). 38% of the

weight of alkaloids is made up of withanine, a class of alkaloids that were separated from the plant's roots (18). The main withanolides that were isolated from *W. somnifera* in India were withanolide D and withaferin A, both of which had cytotoxic and anticancer effects (19). Along with alkaloids, the plant also included glycosides, flavonoids, phenolics, steroids, saponins, and phytophenols (20–23). It is also frequently utilized as an antipyretic, analgesic, adaptogenic, and anti-inflammatory drug in formulations used in traditional medicine (5, 24). A few review papers addressing other facets of *W. somnifera* have been published in the literature (25, 26). To assess the state of the art with regard to the phytochemical composition, therapeutic uses, and nutraceuticals of the miraculous plant *W. somnifera*, a thorough review is still required.




Fig.1: Picture Represents Ashwagandha (*Withania somnifera*)

We focused mostly on the multipurpose plant's preclinical studies, toxicity, and clinical trials. This review will assist in filling in the knowledge gaps about phytochemicals, medicinal chemists, and pharmacologists regarding the medicinal uses and pharmaceutical applications of the beneficial plant. The review evaluated recent research on the high-value uses of plant material in pharmacy and medicine.

Phytochemicals present in *W. Somnifera*:

Plants that are abundant in phytochemicals, including terpenoids, alkaloids, and steroids,

which have been used historically in food and traditional medicine (27–30). By isolating withaniol, somnirol, somnitol, withanic acid, phytosterol, ipuranol, and alkaloids from alcoholic extracts of leaves and roots, Power and Salway began phytochemical investigations of *W. somnifera* in 1911 (31). In the aforementioned investigation, alkaloids were identified and dubbed somniferine, somniferinine, withamine, withanmine, pseudowithamine, and withanaminine (32). Several phytochemicals, including tropine, choline, pseudotropine, dl-isopelletierine, cuscohygrine, anahygrine, and

anaferine, were shown to be present in the plant's alcoholic extract (33). Moreover, the alcoholic root extract of *W. somnifera* was shown to contain withasomnine, a pyrazole alkaloid (34). In 1980, it was reported that a methanolic extract of the plant leaves contained tisopelletierine, 3 α -tigloyloxtropine, cuscohygrine, 3-tropyloigloate, hygrine, isopelletierine, withasomnine, mesoanaferine, withanine, somniferine, hentriacontane, withananine, visamine, ashwagandhine, and pseudowithanine (35). Additionally, withanol, reducing sugars, acylsterylglucosides, ducitol, starch, hantreacotane, iron, and amino acids such as aspartic acid, proline, tyrosine, alanine, glycine, glutamic acid, cysteine, and tryptophan were found in the plant's methanolic extract (20, 21, 36). Fast Atom Bombardment-Mass Spectrometry, ¹³C and ¹H nuclear magnetic resonance (NMR), and UV-visible spectroscopy techniques were used to confirm the structures of seven novel withanosides I–VII that were isolated from a methanolic extract of the plant root (21).

Steroid lactones known as withanolides made up the methanolic extract (37–39). With the exception of the hydroxyl group at C-20 rather than C-27,

withanolide D, which was separated from the alcoholic extract of leaves, showed structural similarities to withaferin A (39).

It is actually 22-hydroxyergostane-26-oic-26,22-olide with novel structural variations at a carboxylic skeleton or side chains that make up 0.001-0.5% of the total dry weight of leaves and roots (41). Depending on their geographic distribution, distinct chemotypes of *W. somnifera* contained varying amounts of substituted steroidal lactones (15, 16, 32, 39, 42).

Withanolide D was mostly found in chemotype-II, which was distinguished by structural change at C-20 with an epoxy system at positions 5 and 6 and a hydroxyl group at position 4. Withanolides E and J, in contrast to other withanolides, had an OH group at C-17 rather than C-20, according to structural characterisation. While withanolides G and J had conventional β -orientation of side chains, withanolides E and F had α -orientation (44). Each chemotype's substituted steroidal lactones were a result of genetic polymorphisms (36) and a thorough analysis of the chemotypes revealed varying steroidal contents (45–50).




Fig.2: Representational image of Huntington's Disease

The alcoholic extract of roots (51) included withanolide A, which was identified as 4 β ,27-dihydroxy-1-oxo-5 β ,6 β -epoxy with a-2,24-dienolide (52). Likewise, the plant's isolated withanolide C has 5 and 6 β epoxide rings with a

chloro-group at C-5(53). An aqueous preparation of the entire plant yielded withanone and tubacapsenolide along with six of its derivatives (54). 2-mercaptoethanol with 5 and 6 β epoxy steroids confirmed the occurrence of 2-en 1-one

with a steroid bearing an epoxy group at positions 6 and 7 in spectroscopic investigations (55). In contrast to withanolide R (56), which lacked an OH group at C-27, withanolide Q has a hydroxyl group at C-23. With the exception of the secondary axial hydroxyl moiety and absence of an epoxide ring, withanolide S, which was isolated from the alcoholic extract of leaves during a biogenetic investigation, shared structural similarities with withanolide E. In addition to the well-known withanolides D, E (16, 39), and P (57), two new withanolides N and O (45) were found in the alcoholic extract of plant leaves. According to quantitative analysis, withaferin A makes about 1.6% of the leaves' total dry weight (58).

Following ethanol extraction, the plant's leaves were examined (59). Pseudotropine, cuscohygrine, isopelletierine, dl-isopelletierine-3-tropyltigloate, anaferine, hygrine, anahygrine, somniferine, mesoanaferine, 3 α -tigloyloxtropine, choline, withanine, visamine, withananine, hentriacontane, and withasomnine, as well as pyrazole derivatives, pseudowithanine, and ashwagandhine, were identified as a number of dragendorff positive alkaloids. Using spectral studies, it was determined that the methanolic extract of shade-dried aerial parts contained diepoxy withanolide, withaferin A, and chlorinated withanolide (27-acetoxy-4 β ,6 α -dihydroxy-5 β -chloro-1-oxowitha-2,24-dienolide), which demonstrated anti-cancerous potential against human lung

cancer (NCI-H460 cell line) (60). From chemotype III, steroidal lactones, withanolide G, and Δ 16-withanolide (61-63) were separated. Using spectroscopic methods and X-ray crystallographic analysis, the entire plant extracted with equimolar ratios of water and methanol was examined and found to contain nine known withanolides, including (22R)-5 β -formyl-6 β ,27-dihydroxy-1-oxo-4-norwith-24-enolide, 6 α -chloro-5 β hydroxywithaferin A, 2,3-dihydrowithaferin A, withaferin A, withanone, 3-methoxy-2,3-dihydrowithaferin A, withanoside IV, 2,3-didehydrosomnifericin, and withanoside X. An analysis of the plant's ethanol extract revealed that it contained sominone, isosominolide, and asomniferin A (64, 65). As is typical of most withanolides, withasommidienone, which was separated from the plant's methanolic root extract, displayed three double bonds at positions 1, 4, and 24 (68). Withaoxylactone and somnifericin were extracted from the plant and described using a variety of methods in a different study. The presence of four epoxy groups at various locations in withaoxylactone (5, 6, 14, and 15 places) and somnifericin (4, 5, 6, and 27 positions) was revealed (69). An ethanolic extract of stem bark was found to contain five unique withanolides, including withasomnilide, somniferanolide, somniferawithanolide, and withasomniferanolide, according to another experiment.




Fig.3: Represents gene protein linkage of neurodegeneration of HD

*Withania somniferan*olide, *somnifera* withanolide, and *somniwithanolide* do not contain epoxy groups, according to additional analysis (70). In a similar manner, three novel withanolides were identified, including *withasomniferol A*, *withasomniferol B*, and *withasomniferol C* from root extracts in benzene and ethyl acetate (71). Isolated from alcoholic fruit, *deoxywithaperuv*in Spectral analysis was used to characterize the extract and discovered Five hydroxyl moieties are present at positions 5, 6, 14, 17, and 20 positions (72).


The alcoholic extract contains *viscosalactone B* examined the entire facility as a structural *Withaferin* analog containing an epoxy group at position six and three hydroxyl groups, seven locations, and a double bond at C-24 groups on the carbon skeleton at positions 3, 4, and 27 (73). The identification of withanolide Y was 5α , 6α -epoxy- 7α , 17α , Utilizing 20R-trihydroxy-1-oxo-22R-witha-2, 24-dienolide XRD on a single crystal (74).

To isolate the phytochemicals, the plant's roots were extracted using petroleum ether and acetone. β -sitosterol and d-glycoside were shown to be present using a variety of chromatographic and spectroscopic methods (75).

50 g of *W. somnifera* powder and 500 ml of distilled water were subjected to subcritical water extraction of withanolides at 40 °C. After lyophilizing the extract, high-performance liquid chromatography and Soxhlet were used to separate the withanolides.

The findings demonstrated that the real biological components in charge of the different biological actions were withanoside IV, 12-Deoxywithastramonolide, *withaferin A*, and withanolide A (76). Caffeic, ferulic, and benzoic acids, as well as *withaferin A*, *withanone*, and withanolide A, were extracted from *W. somnifera* root, stem, and leaves using methanolic and chloroform extracts at a concentration of 4.0 g per plant component (77).

GC-MS analysis of various oil extracts from *W. somnifera* berries revealed saturated and unsaturated fatty acids such as linoleic acid (11.247%), palmitic acid (2.842%), linoleic acid (4.000%), tetracosanoic acid (0.880%), palmitic acid (0.42%), elaidic acid (0.01%), linoleic acid (0.23%), and oleic acid (0.14%) (95). The extracts contained nine withanolides: 27-hydroxy *withanone*, 17-hydroxy-27-deoxy *withaferin A*, 17-hydroxy *withaferin A*, withanolide D, *withaferin A*, withanolide A, 27-hydroxy withanolide B, *withanone*, and 27-deoxywithaferin A (77).



Folk Medicinal Uses:

The plant's many parts, including leaves, roots, blossoms, bark, and stem, have traditionally been used to treat heart problems, pain, liver disorders, fever, respiratory infections, wounds, ulcers, and sex-related ailments (112-113). The therapeutic capacity of plants utilized in ancient medicinal systems (Unani and Ayurvedic) was attributed to bio actives such as alkaloids, steroids, phenolics, flavonoids, and so on (2,113). Among other plants in the *Withania* genus, *W. somnifera* is high in the aforementioned bio actives, making it the preferred choice of folk healers (114-117).

Pharmacological attributes:

Antifungal and Antimicrobial activities:

The plant also inhibited bursal disease virus in a cytopathic effect reduction experiment (117). Monomeric glycoprotein extracted from the plant's root tuber suppressed the growth of fungi like *Fusarium oxysporum*, *Aspergillus flavus*, and *Fusarium verticillioides*, as well as bacteria like *Clvibacter michiganensis* subsp. *michiganensis* (123). The bactericidal potential of aqueous and alcoholic root extracts was assessed using the agar well diffusion experiment. The butanolic subfraction of the plant's methanolic root/leaf extract exhibited significant antibacterial potential against *Salmonella typhimurium*, whereas oral administration of *W. somnifera*'s aqueous leaf/root extract exhibited bacteriostatic effect against *S. typhimurium* similar to chloramphenicol, the standard drug (124). The plant's leaf, root, and stem extracts were tested for bactericidal activity against six bacterial strains (*Staphylococcus aureus*, *Bacillus subtilis*, *Escherichia coli*, *Raoultella planticola*, *Pseudomonas aeruginosa*, *Enterobacter aerogens*) and fungistatic activity against *Candida albicans* and *A. flavus* using serial dilution and disc diffusion methods. The aqueous

leaf extract had the strongest activity against *R. planticola*, whereas the others had intermediate antibacterial and fungistatic properties (150-152). Several plant extracts and isolated chemicals showed promise as antibacterial and antifungal agents (164). In another study, the plant's leaves and roots were extracted with methanol, diethyl ether, and n-hexane and tested for antibacterial activity against *S. typhimurium* and *E. coli* using an agar plate diffusion assay. The methanol and hexane-based extract demonstrated significant antibacterial activity. Tibrim's antibacterial activity increased significantly when combined with plant extracts in methanol and hexane (165). A 10 µg/ml concentration of methanolic root extract inhibited *E. coli* and *Enterococcus* species growth (97). The methanolic extract of roots, leaves, and bark inhibited the development of Gram-positive (*S. aureus*) and negative (*E. coli*) bacterial strains at concentrations ranging from 10-100 µg/mL. Methanoic extracts from roots and leaves were tested against fungi such *A. flavus*, *D. turcica*, and *F. verticillioides* at a concentration of 100 µg. Nystatin was used as a positive control.




Fig.3: shows Brain causing Huntington protein binding linkage in A and B

The zone of greatest inhibition against fungal strains was observed to be between 7 and 14 mm

(166). A methanolic extract of the leaves inhibited the growth of *Enterococcus* species and *S. aureus* at a concentration of 1-2 mg/ml (167).

Acetone, methanol, ethanol, and chloroform extracts of plant roots showed significant microbicidal activity against *S. aureus* and *K. pneumonia* (168).

The plant extracts (leaf, stem, and root) were tested for antifungal activity against *F. crown* at a concentration of 100 mg/100 ml solvent.

Aqueous and organic solvent extracts of the plant showed significant suppression at 5-45 mm compared to the positive control, dimethyl sulfoxide (DMSO) (169).

Antidote activity:

Snake venom consists of myo, neuro, cyto, and enzymatic-toxins (155). Recently, antidote properties of *W. somnifera* are reported against toxicity induced by arsenic (115).

Hyaluronidases enzymes present in snake venom helped the dispersal of toxins in the extracellular matrix of the tissues in victims. A glycoprotein from *W. somnifera* inhibited hyaluronidase in the venom of Naga raja (cobra) and *Daboia russelii* (viper) when tested using the zymogram assay. The extracts also inhibited the activity of phospholipase A-2, an enzymatic toxin found in cobra venom (156,170).

Another study found that an aqueous extract of *W. somnifera* (whole plant) reduced the harmful effects of PLA-2 caused by Naja raja venom (171).

	Cognitively intact	MCI: mild disability	MCI: working memory	MCI: executive planning	MCI: information integrative	MCI: memory processing	MCI: learning-memory
N (% of total prodromal HD sample)	237 (67%)	120 (33%)	94 (27%)	92 (26%)	340 (91%)	143 (39%)	214 (59%)
Continuous variables							
Age							
Mean	46.3	38.7	41.3	40.8	38.8*	42.5*	40.2
SD	9.4	9.0	10.0	9.8	10.4	11.1	10.0
Range	[21.8, 72.9]	[20.3, 85.7]	[25.0, 85.6]	[18.1, 75.8]	[20.0, 87.8]	[18.3, 75.9]	[23.0, 75.8]
CAP							
Mean	316.4	379.9**	368.8**	356.9**	386.0**	391.0**	388.9**
SD	75.7	88.7	82.7	87.4	88.8	88.1	90.4
Range	[142.7, 523.5]	[168.3, 845.8]	[168.2, 822.0]	[168.1, 845.8]	[111.1, 845.8]	[118.0, 852.3]	[163.3, 845.8]
TMS							
Mean	3.3	10.1**	9.0**	7.6**	8.8**	7.9**	6.0**
SD	3.5	9.7	9.1	8.4	8.7	9.3	7.9
Range	[0, 30]	[0, 47]	[0, 44]	[0, 34]	[0, 47]	[0, 47]	[0, 44]
Categorical variables n (%)							
Sex							
Female	232 (98.3)	80 (67.5)	57 (60.6)	157 (75.5)**	130 (57.3)**	66 (46.2)**	130 (64.8)**
Male	5 (2.0)	40 (33.5)	37 (39.4)	45 (21.2)	110 (42.7)	79 (53.8)	119 (55.4)
Race							
White	347 (97.5)	128 (96.8)	94 (100)	147 (68.5)	236 (86.5)	109 (75.5)	207 (96.7)
Others	10 (2.8)	4 (3.2)	0 (0)	3 (1.5)	4 (1.5)	14 (9.5)	7 (3.3)

MCI: Mild Cognitive Impairment; CAP: CAGE; Age: Product; TMS: Total Motor Score from the Unified HD Rating Scale.

** p < 0.001; *** p < 0.01; **** p < 0.001.

Table 1: shows the cognitive function of brain during Huntington's disease

Pesticidal and larvicidal activity:

Aqueous, methanol, and n-hexane extracts of roots and shoots (5, 10, 15, and 20% weight and volume) were tested against *Phalaris minor* in crops. Aqueous sprouts and root extracts have much higher herbicidal efficacy against *P. minor* than other solvent extracts (116). Root and shoot extracts in methanol, water, and n-hexane had considerable herbicidal efficacy. *Parthenium hysterophorus* germination and seedlings were

found to be reduced after applying aqueous and methanolic extracts by foliar spray or soil (133).

Withania somnifera (Ashwagandha) has a number of phytochemicals that contribute to its capacity to relieve stress and anxiety. These bioactive chemicals function through a variety of pathways, which contribute to their adaptogenic capabilities. Here are the primary compounds present in Ashwagandha that help to alleviate stress and anxiety:



Withanolides:

- Withanolides, the primary bioactive components in ashwagandha, are a type of naturally occurring steroid.
- They exhibit anti-inflammatory, antioxidant, and neuroprotective effects. Withanolides modulate the stress response by lowering cortisol (the stress hormone) levels, and they can also protect the brain and nervous system from stress-related damage.
- Withaferin A, a kind of withanolide, has been investigated for its capacity to lower anxiety and improve mood by altering the activity of GABA receptors, which are important in calming the nervous system.

Alkaloids:

- Ashwagandha includes numerous alkaloids, including somniferine, anaferrine, and tropine.
- These alkaloids are thought to operate as calming agents on the central nervous system, reducing symptoms of anxiety and encouraging relaxation.

Saponins:

- Ashwagandha saponins, including withanosides, have adaptogenic and antioxidant effects. They assist the body deal with physical and emotional stress.
- Saponins also help the immune system and improve the body's ability to recuperate from stress by lowering inflammation and oxidative stress levels.

Flavonoids:

- Ashwagandha contains flavonoids, which are well known for their antioxidant properties.
- These compounds help to reduce oxidative stress, which is caused by chronic anxiety or

stress. Flavonoids help to maintain overall health and a healthy stress response by protecting cells from oxidative damage.

Triterpenoids:

- Ashwagandha contains triterpenoids, which have anti-inflammatory and neuroprotective properties.
- These substances may help balance the body's reaction to stress by protecting the brain and neurological system from the negative effects of prolonged stress.

Fatty acids:

- Ashwagandha contains a variety of fatty acids, including linoleic and oleic acid, which are essential for brain health.
- These fatty acids aid to improve the structure and function of the nervous system, boosting mental clarity, attention, and reducing anxiety.

Iron:

- Ashwagandha includes iron, which can help boost energy and alleviate fatigue, a typical side effect of prolonged stress.

Acetylglucosamine:

- Acetylglucosamine is another molecule in Ashwagandha that supports the neurological system and helps neurons stay healthy, potentially helping to reduce stress-induced brain damage.

Mechanism of action for stress and anxiety:

1. **Cortisol regulation:** One of Ashwagandha's most well-studied benefits is its ability to regulate cortisol levels, which rise during times of stress. Lowering cortisol helps to



alleviate the physical and mental symptoms of stress and anxiety.

2. **GABA modulation:** Ashwagandha can interact with GABA receptors, which help to reduce hyperactive brain activity and promote feelings of calm and relaxation.
3. **Neurogenesis:** Ashwagandha has been proven to promote neurogenesis, which aids in the healing and regeneration of nerve cells, particularly in areas of the brain involved in emotional regulation and memory, such as the hippocampus.

CONCLUSION:

Withania somnifera, also known as Ashwagandha, has emerged as a powerful and widely utilized plant in the field of natural stress and anxiety relief. Its lengthy history in traditional medicine, notably Ayurvedic techniques, has paved the way for its modern-day use in promoting mental health. The herb's potential to serve as an adaptogen is one of the primary factors that contribute to its efficacy in stress management. Adaptogens are compounds that assist the body resist and adapt to various types of stress, both physical and mental, by balancing physiological systems and promoting homeostasis.

Withania somnifera's principal bioactive components, particularly withanolides, play an important function in stress reduction. Withanolides help to regulate cortisol levels, which are usually raised in response to stress. Cortisol levels can have a variety of negative effects, including increased anxiety, exhaustion, and reduced cognitive performance. Ashwagandha reduces the body's stress response by moderating cortisol secretion, promoting calmness and mental clarity. This makes it a natural alternative to synthetic anti-anxiety drugs, which are frequently associated with negative side effects.

Beyond cortisol modulation, *Withania somnifera* has a variety of bioactive components, including alkaloids, saponins, flavonoids, and fatty acids, which work together to promote mental wellness. Alkaloids such as somniferine contribute to Ashwagandha's relaxing effects, whereas saponins improve the body's ability to cope with stress by strengthening the immune system and lowering inflammation. Flavonoids, with their antioxidant capabilities, protect the brain from oxidative stress, thereby promoting cognitive performance and mood stability. Furthermore, the fatty acids in Ashwagandha have neuroprotective properties, which protect brain cells from stress-induced damage.

Ashwagandha's impact on mental health extends beyond its physiological benefits. The herb has been found to improve the body's stress resistance by stimulating neurogenesis, particularly in parts of the brain involved in emotional regulation, such as the hippocampus. This nerve regeneration process promotes emotional equilibrium and aids the brain's recovery from the negative effects of chronic stress. Furthermore, Ashwagandha's capacity to interact with GABA receptors, which play an important role in relaxing brain activity, enhances its ability to produce relaxation and alleviate anxiety symptoms.

Numerous scientific investigations and clinical trials have shown that Ashwagandha is effective in lowering both psychological and physiological symptoms of stress and anxiety. Many people who have incorporated Ashwagandha into their daily routines report a significant reduction in anxiety, improved mood, and general emotional well-being. The herb's moderate yet effective approach to stress management, combined with its low risk of side effects, has made it a popular choice among those looking for a natural solution to their mental health issues.



In conclusion, *Withania somnifera* is an effective natural therapy for stress and anxiety. Its unique combination of phytochemicals, mainly withanolides, alkaloids, and saponins, works together to control the body's stress response, reduce anxiety, and improve emotional resilience. Ashwagandha's adaptogenic, neuroprotective, and relaxing characteristics provide a comprehensive approach to addressing the consequences of chronic stress and anxiety. As further study is conducted to uncover its full range of advantages, *Withania somnifera* is positioned to remain a vital and trusted ally in boosting mental health and wellness. Ashwagandha, whether taken alone or as part of a larger health regimen, is a natural, effective alternative for people looking to restore balance and tranquillity in their life in the face of modern stressors.

REFERENCE

1. Ashraf MU, Muhammad G, Hussain MA, Bukhari SN. *Cydonia oblonga* M., A medicinal plant rich in phytonutrients for pharmaceuticals. *Front Pharma* 2016; 7:163-183.
2. Anwar F, Muhammad G, Hussain MA, Zengin G, Alkharfy KM, Ashraf M, et al. *Capparis spinosa* L: a plant with high potential for development of functional foods and nutraceuticals/ pharmaceuticals. *Int J Pharma* 2016; 12:201-219.
3. Jana NS, Charan SM. Health benefits and medicinal potency of *W somnifera*: A review. *Int Pharm Sci Rev Res* 2018; 48:22-29.
4. Nazar S, Hussain MA, Khan A, Muhammad G, Tahir MN. *Capparis decidua* Edgew (Forssk.): a comprehensive review of its traditional uses, phytochemistry, pharmacology and nutraceutical potential. *Arab J Chem* 2018; 13:1901-1916.
5. Kalra R, Kaushik N. *Withania somnifera* (Linn.) Dunal: a review of chemical and pharmacological diversity. *Phytochem Rev* 2017; 16:953-987.
6. Verma SK, Kumar A. Therapeutic uses of *Withania somnifera* (Ashwagandha) with a note on withanolides and its pharmacological actions. *Asian J Pharm Clin Res* 2011; 4:1-4.
7. Singh S, Kumar S. *Withania somnifera*: The Indian ginseng Ashwagandha. Central Institute of Medicinal and Aromatic Plants, Lucknow 1998; 2.
8. Hepper FN. Old world *Withania* (Solanaceae): a taxonomic review and key to the species. In: Hawkes JG, Lester RN, Estrada N. (eds) *Solanaceae III: Taxonomy, chemistry, evolution*. RBG Kew, Richmond, Surrey. 1991:211-227.
9. Bhandari MM. *Flora of the Indian desert*, MPS Repros Jodhpur, India. 1995. <http://www.cazri.res.in/annals/1967/1967S-13.pdf>.
10. Bhattacharya A, Ramanathan M, Ghosal S. Effect of *Withania somnifera* glycowithanolides on iron-induced hepatotoxicity in rats. *Phytother Res* 2000; 14:568-570.
11. Kuboyama T, Tohda C, Komatsu K. Neuritic regeneration and synaptic reconstruction induced by withanolide A. *British J Pharma* 2005; 144: 961-971.
12. Bhattacharya SK, Bhattacharya A, Sairam K, Ghosal S. Anxiolytic-antidepressant activity of *Withania somnifera* glycowithanolides: an experimental study. *Phytomed* 2000; 6:463-469.
13. Ahmad M, Saleem S, Ahmad AS, Ansari MA, Yousuf S, Hoda MN, et al. Neuroprotective effects of *Withania somnifera* on 6 hydroxydopamine induced



- parkinsonism in rats. *Human Exp Tox* 2005; 24:137-147.
14. Visavadiya NP, Narasimhacharya AV. Hypocholesteremic and antioxidant effects of *Withania somnifera* (Dunal) in hypercholesteremic rats. *Phytomed* 2007; 14:136-142.
15. Schmelze GH, Gurib-Fakim A, Arroo RRJ, Bosch CH, de Ruijter A, Simmonds MSJ. *Plant resources of tropical Africa 11(1)—medicinal plants* Backhuys Publishers, Wageningen. 2008; 630.
16. Lavie D, Kirson I, Glotter E, Rabinovich D, Shakked Z. Crystal and molecular structure of withanolide E, a new natural steroidal lactone with a 17 α -side-chain. *J Chem Soc Chem Comm* 1972; 15:877-878.
17. Glotter E, Kirson I, Abraham A, Lavie D. Constituents of *Withania somnifera* (Dunal) XIII—the withanolides of chemotype III. *Tetrahed* 1973; 29:1353-1364.
18. Atal CK, Dhar KL, Gupta OP, Raghunathan K. *Pharmacognosy and phytochemistry of Withania somnifera* (Linn.) Dunal (Ashwagandha). Central Council for Research in Indian Medicine and Homeopathy, New Delhi. 1975.
19. Yoshida M, Hoshi A, Kureitani K, Ishiguro M, Ikekawa N. Relationship between chemical structure and antitumor activity of withaferin A analogues. *J Pharmacobiodyn* 1979; 2:92-97.
20. Alam N, Hossain M, Khalil MI, Moniruzzaman M, Sulaiman SA, Gan SH. High catechin concentrations detected in *Withania somnifera* (ashwagandha) by high performance liquid chromatography analysis. *Altr Med* 2011; 11:65-69.
21. Mirjalili MH, Moyano E, Bonfill M, Cusido RM, Palazon J. *Iran J Basic Med Sci*, Vol. 23, No. 12, Dec 2020 1519 Saleem et al. An overview of *Withania somnifera* L. Steroidal lactones from *Withania somnifera*, an ancient plant for novel medicine. *Mole* 2009; 14:2373-2393.
22. Divisha R, Ranganathan V, Vijayakaran K, Elamaram A, Senthil KP. Quantifying phytophenols in *Andrographis paniculata* and *Withania somnifera* leaf extract. *J Pharam* 2018; 7:477-479.
23. Das S, Saraf A, Sharma D, Sohal JK. Qualitative screening of bioactive secondary metabolites present in *Withania somnifera* and *Rauwolfia serpentina* root and stem extract with pharmacological importance. *Int J Res Ana Rev* 2019; 6:69-74.
24. Chopra RN, Chopra IC, Handa KL, Kapur LD. *Withania somnifera* Duna, Indigenous drugs of India. U N Dhar and Sons, Calcutta. 1958:436-437.
25. Tripathi N, Shrivastava D, Mir BA, Kumar S, Govil S, Vahedi M, Bisen PS. Metabolomic and biotechnological approaches to determine therapeutic potential of *Withania somnifera* (L.) Dunal: A Review. *Phytomed* 2018; 50:127-136.
26. Durg S, Shivaram SB, Bavage S. *Withania somnifera* (Indian ginseng) in male infertility: An evidence-based systematic review and meta-analysis. *Phytomed* 2017; 50 247-256.
27. Saleem S, Muhammad G, Hussain MA, Bukhari SNA. A comprehensive review of phytochemical profile, bioactives for pharmaceuticals, and pharmacological attributes of *Azadirachta indica*. *Phytother Res* 2018; 32:1241-1272.
28. Muhammad G, Asghar MN, Ahmad M, Kashmiri MA, Zia I. Antioxidant and antimicrobial activities of extracts from aerial parts of *Alhagi pseudalhagi*. *Asian J Chem* 2011; 23:971.
29. Hussain MA, Muhammad G, Jantan I, Bukhari SNA. *Psyllium arabinoxylan*: A



- versatile biomaterial for potential medicinal and pharmaceutical applications. *Polym Rev* 2016; 56: 1-30.
30. Aye MM, Aung HT, Sein MM, Armijos C. A review on the phytochemistry, medicinal properties and pharmacological activities of 15 selected myanmar medicinal plants. *Molecules* 2019; 24:293-327.
31. Power FB, Salway AH. The constituents of *Withania somnifera*. *J Chem Soc* 1911; 99:490-507.
32. Majumdar DN. Alkaloid constituents of *Withania somnifera*. *Curr Sci* 1952; 21:46-48.
33. Schwarting AE, Bobbit JM, Rother A, Atal CK, Khanna KL, Leary JD, et al. The alkaloids of *Withania somnifera*. *Llyoida* 1963; 26:258-273.
34. Schröter HB, Neumann D, Katritzky AR, Swinbourne FJ. Withasomnine: A pyrazole alkaloid from *Withania somnifera* Dun. *Tetrahed* 1966; 22:2895-2897.
35. Kirson I, Glotter E. 14 α -hydroxy steroids from *Withania somnifera* (L) Dunal. *J Chem Res Syn* 1980; 10:338-339.
36. Abraham A, Kirson I, Glotter E, Lavie D. A chemotaxonomic study of *Withania somnifera* (L.) Dunal. *Phytochem* 1968; 7:957-962.
37. Lavie D, Glotter E, Shvo Y. Constituents of *Withania somnifera*—III—the side chain of Withaferin A. *J Org Chem* 1965; 30:7517-7531.
38. Lavie D, Field SG, Glotter E. Constituents of *Withania somnifera* Dun. Part VI. The stereochemistry of withaferin A. *J Chem Soc C* 1966; 19:1753-1756.
39. Lavie D, Kirson I, Glotter E. Constituents of *Withania somnifera* part X. The structure of withanolide D. *Isr J Chem* 1968; 5:671-678.
40. Kapoor LD. *Handbook of Ayurvedic medicinal plants*. CRC Press. 2001.
41. Cardenas J, Esquinel B, Gupta M, Ray AB, Rodriguez H. *Progress in chemistry of organic natural products*. Springer Wien, Austria. 1994; 63:77.
42. Abraham A, Kirson I, Lavie D, Glotter E. The withanolides of *Withania somnifera* chemotypes I and II. *Phytoche* 1975; 1520 14:189-194.
43. Rastogi RP, Mehrotra BN. *Compendium of Indian medicinal plants*, 2nd Reprint, Central Drug Research Institute, Lucknow and National Institute of Science Communication, Council of Scientific and Industrial Research. New Delhi 1998:434-436.
44. Choudhary MI, Yousuf S, Nawaz SA, Ahmad S, Rahman AU. Cholinesterase inhibiting withanolides from *Withania somnifera*. *Chem Pharma Bulletin* 2004; 52: 1358-1361.
45. Ganzera M, Choudhary MI, Khan IA. Quantitative HPLC analysis of withanolides in *Withania somnifera*. *Fitoterapia* 2003; 74:68-76.
46. Kirson I, Abraham A, Lavi D. Chemical analysis of hybrids of *Withania somnifera*(L) Dun Chemotype III (Israel) by Indian I (Delhi). *Isr J Chem* 1977; 16:20-24.
47. Leyon PV, Kuttan G. Effect of *Withania somnifera* on B16F-10 melanoma induced metastasis in mice. *Phytother Res* 2004; 18:118-122.
48. Ray S, Jha S. Production of withaferin A in shoot cultures of *Withania somnifera*. *Planta Medica* 2001; 67:432-436.
49. Sethi PD, Subramanian SS. Steroidal constituents of *Withania coagulans* roots. *Ind J Pharm* 1976; 38:22-23.
50. Shohat B, Kirson I, Lavie D. Immunodepressive properties of withaferin and withanolide D. *Biomed* 1978; 28:18-23.

51. Menssen HG, Stapel G. A C28-steroidlacton from the roots of *Withania somnifera* (author's transl). *Planta Medica* 1973; 24:8-12.
52. Tursunova RN, Maslennikova VA, Abubakirov NK. Withanolides in the vegetable kingdom. *Chem Nat Comp* 1977; 13:131-138.
53. Bessalle R, Lavie D. Withanolide C, a chlorinated withanolide from *Withania somnifera*. *Phytochem*. 1992; 3:3648-3651.
54. Kirson I, Glotter E, Lavis D, Abraham A. Constituents of *Withania somnifera* Dunal XII. The withanolides of an Indian chemotype. *J Chem Soc* 1971; 52:2032-2044.
55. Misra L, Mishra P, Pandey A, Sangwan RS, Sangwan NS, Tuli R. Withanolides from *Withania somnifera* roots. *Phytochem* 2008; 69:1000-1004.
56. Kirson I, Cohen A, Abraham A. Withanolides Q and R, two new 23-hydroxy-steroidal lactones. *J Chem Soc Perkins Trans* 1975; 21:2136-2138.
57. Glotter E, Abraham A, Gunzberg G, Kirson I. Naturally occurring steroidal lactones with a 17- α oriented side chain. Structure of withanolide E and related compounds. *J Chem Society Perkin Trans*. 1977; 1:341-346.
58. Gupta AP, Verma RK, Misra HO, Gupta MM. Quantitative determination of withaferin A in different plant parts of *Withania somnifera* by TLC densitometry. *J Med Arom Plant Sci* 1996; 18:788-790.
59. Bandhoria P, Gupta VK, Amina M, Satti NK, Dutt P, Suri KA. 6 α ,7 α -epoxy-5 α ,17 α , dihydroxy-1-oxo-22R-witha-2,24 dienolide in leaves of *Withania somnifera*: isolation and its crystal structure. *J Chem Crystal* 2006; 36:153-159.
60. Choudhary MI, Hussain S, Yousuf S, Dar A, Mudassar, Rahman AU. Chlorinated and diepoxy withanolides from *Withania somnifera* and their cytotoxic effects against human lung cancer cell line. *Phytochem* 2010; 71:2205-2209.
61. Tong X, Zhang H, Timmermann BN. Chlorinated withanolides from *Withania somnifera*. *Phytochem Lett* 2011; 4:411-414.
62. Velde VV, Lavie D. New withanolides of biogenetic interest from *Withania somnifera*. *Phytochem* 1981; 20:1359-1364.
63. Velde VV, Lavie D. A Δ 16-withanolide in *Withania somnifera* as a possible precursor for α -side-chains. *Iran J Basic Med Sci*, Vol. 23, No. 12, Dec 2020 An overview of *Withania somnifera* L. Saleem et al. *Phytochem* 1982; 21:731-733.
64. Rahman AU, Jamal SA, Choudhary MI, Asif E. Two withanolides from *Withania somnifera*. *Phytochem* 1991; 30:3824-3826.
65. Rahman AU, Jamal SA, Choudhary MI. Two new withanolides from *Withania somnifera*. *Phytochem* 1991; 30:3824-3826.
66. Eastwood FW, Kirson I, Lavie D, Abraham A. Analysis of hybrids of *Withania somnifera* part 2. New withanolides from a cross of South African chemotype by chemotype II (Israel) in *Withania somnifera*. *Phytochem* 1980; 19:1503-1507.
67. Lavie D, Kirson I, Abraham A. Chemical approach to genetics. *Isr J Chem* 1975; 14:60-68.
68. Rahman AU, Abbas S, Shahwar DE, Jamal SA, Choudhary MI. New withanolides from *Withania* spp. *J Nat Prod* 1993; 56:1000-1006.
69. Choudhary MI, Abbas S, Jamal SA, Rahman AU. *Withania somnifera*: a source of exotic withanolides. *Heterocycles* 1996; 42:555-563.

70. Ali M, Shuaib M, Ansari SH. Withanolides from the stem bark of *Withania somnifera*. *Phytochem* 1997; 44:1163-1168.
71. Anjaneyulu ASR, Rao SD. New withanolides from the roots of *Withania somnifera*. *Ind J Chem* 1997; 36:424-433.
72. Abou-Douh AM. New withanolides and other constituents from the fruit of *Withania somnifera*. *Int J Pharm Med Chem* 2002; 335:267-276.
73. Jayaprakasam B, Nair MG. Cyclooxygenase-2 enzyme inhibitory withanolides from *Withania somnifera* leaves. *Tetrahed* 2003; 59:841-849.
74. Bessalle R, Lavie D. Semiquantitative reverse phase high performance liquid chromatography analysis of the ecotypes of *Withania somnifera* chemotype III. *J Chr A* 1987; 389:195-210.
75. Trivedi PC, Choudhrey N. Isolation and characterization of bioactive compound sitosterol from *Withania somnifera* L. *J Pharma Res* 2011; 4:4252-4253.
76. Nile SH, Nile A, Gansukh E, Baskar V, Kai G. Sub critical water extraction of withanoid and withanolide from ashwagandha (*Withania somnifera* L) and their biological activities. *Food Chem Tox* 2019; 132:110659-110668.
77. Tomar V, Beuerle T, Sircar D. A validated HPTLC method for the simultaneous quantification of three phenolic acids and three withanolides from *Withania somnifera* and its herbal products. *J Chrom B* 2019; 1124:154-160.
78. Malik F, Singh J, Khajuria A, Suri KA, Satti NK, Singh S, et al. A standardized root extract of *Withania somnifera* and its major constituent withanolide-A elicit humoral and cell-mediated immune responses by up regulation of Th1 dominant polarization in BALB/c mice. *Life Sci* 2007; 80:1525-1538.
79. Chaurasiya ND, Uniyal GC, Lal P, Misra L, Sangwan NS, Tuli R, et al. Analysis of withanolides in root and leaf of *Withania somnifera* by HPLC with photodiode array and evaporative light scattering detection. *Phytochem Ann* 2008; 19:148-154.
80. Singh G, Sharma PK, Dudhe R, Singh S. Biological activities of *Withania somnifera*. *Ann Bio Res* 2010; 1:56-63.
81. Davis L, Kuttan G. Effect of *Withania somnifera* on cell mediated immune responses in mice. *J Exp Clin Can Res* 2002; 21:585-590.
82. Pramanick S, Roy A, Ghosh A, Majumder HK, Mukhopadhyay S. Withanolide Z, a new chlorinated withanolide from *Withania somnifera*. *Planta Medica* 2008; 74:1745-1748.
83. Seth C, Mas C, Conod A, Mueller J, Siems K, Kuciak M. Long-lasting WNT-TCF response blocking and epigenetic modifying activities of withanolide F in human cancer cells. *PLoS ONE* 2011; 11: 168170-168189.
84. Nittala SS, Lavie D. Chemistry and genetics of withanolides in *Withania somnifera* hybrids. *Phytochem* 1981; 20:2741-2748.
85. Jayaprakasam B, Zhang Y, Seeram NP, Nair MG. Growth inhibition of human tumor cell lines by withanolides from *Withania somnifera* leaves. *Life Sci* 2003; 74:125-132.
86. Zhao J, Nakamura N, Hattori M, Kuboyama T, Tohda C, Komatsu K. Withanolide derivatives from the roots of *Withania somnifera* and their neurite outgrowth activities. *Chem Pharm Bull* 2002; 50:760-765.
87. Bhattacharya SK, Muruganandam AV. Adaptogenic activity of *Withania somnifera*: an experimental study using a rat model of chronic stress. *Pharma Biochem Behav* 2003; 75:547-555.



88. Kaileh M, Vanden WB, Heyerick A, Horion J, Piette J, Libert C, et al. Withaferin A strongly elicits I κ B kinase β hyperphosphorylation concomitant with potent inhibition of its kinase activity. *J Bio Chem* 2007; 282:4253-4264.
89. Mohan R, Hammers H, Bargagna-Mohan P, Zhan X, Herbstritt C, Ruiz A, et al. Withaferin A is a potent inhibitor of angiogenesis. *Angiogen* 2004; 7:115-122.
90. Mondal S, Roy S, Maity R, Mallick A, Sangwan R, Misra Bhattacharya S, Mandal C. Withanolide D, carrying the baton of Indian rasayana herb as a lead candidate of antileukemic agent in modern medicine. In *Biochem Roles Eukar Cell Surf Macromol* 2012; 749:295-312.
91. Thoda C, Joyashiki E. Sominone enhances neurite outgrowth and spatial memory mediated by the neurotrophic factor receptor. *Br J Pharmacol* 2009; 157:1427-1440.
92. Naidu PS, Singh A, Kulkarni SK. Effect of *Withania somnifera* root extract on reserpine-induced orofacial dyskinesia and cognitive dysfunction. *Phytother Res* 2006; 20:140-146.
93. Misra L, Rajender PL, Sangwan S, Neelam S, Sangwan S, Uniyal GC, et al. Unusually sulfated and oxygenated steroids from *Withania somnifera*. *Phytochem* 2005; 66:2702-2707.
94. Iuvone T, Esposito G, Capasso F, Izzo A. Induction of nitric oxide synthase expression by *Withania somnifera* in macrophages. *Life Sci* 2003; 72:1617-1625.
95. Uddin G, Gul S, Rauf A. Preliminary phytochemical screening, in vitro antimicrobial and antioxidant evaluation of *Withania somnifera* Dunal. *World App Sci J* 2013; 27:562-565.
96. Chatterjee S, Srivastava S, Khalid A, Singh N, Sangwan RS, Sidhu OP, et al. Comprehensive metabolic fingerprinting of *Withania somnifera* leaf and root extracts. *Phytochem* 2010; 71:1085-1094.
97. Mathur RS, Gupta SK, Singh N, Mathur S, Kochupillai V, Velpandian T. Evaluation of the effect of *Withania somnifera* root extracts on cell cycle and angiogenesis. *J Ethnopharma* 2006; 105:336-341.
98. Jayaprakasam B, Strasburg GA, Nair MG. Potent lipid peroxidation inhibitors from *Withania somnifera* fruits. *Tetrahed* 2004; 60:3109-3121.
99. Lal P, Misra L, Sangwan RS, Sangwan NS, Tuli R. New withanolides from fresh berries of *Withania somnifera*. *J Chem Sci* 2006; 61:143-1147.
100. Subbaraju GV, Vanisree M, Rao CV, Sivaramakrishna C, Sridhar P, Jayaprakasam B, et al. Ashwagandhanolide, a bioactive dimeric thiowithanolide isolated from the roots of *Withania somnifera*. *J Nat Prod* 2006; 69:1790-1792.
101. Matsuda H, Murakami T, Kishi A, Yoshikawa M. Structures of withanosides I, II, III, IV, V, VI, and VII, new withanolide glycosides, from the roots of Indian *Withania somnifera* dunal and inhibitory activity for tachyphylaxis to clonidine in isolated guinea-pig ileum. *Bioorg Med Chem* 2001; 9:1499-1507.
102. Xu YM, Marron MT, Seddon E, McLaughlin SP, Ray DT, Iran J Basic Med Sci, Vol. 23, No. 12, Dec 2020 1521 Saleem et al. An overview of *Withania somnifera* L. Whitesell L, et al. 2,3-Dihydrowithaferin A-3 β -O-sulfate, a new potential prodrug of withaferin A from aeroponically grown *Withania somnifera*. *Bioorg Med Chem* 2009; 17:2210-2214.



103. Xu YM, Gao S, Bunting DP, Leslie AA, Gunatilaka. Unusual withanolides from aeroponically grown *Withania somnifera*. *Phytochem* 2011; 72:518-522.
104. Subramanian SS, Sethi PD. Withaferin-A from the roots of *Withania coagulans*. *Curr Sci* 1969; 38:267-268.
105. Subramanian SS, Sethi E. 5, 20 [α](R)-dihydroxy-6 [α], 7 [α]-epoxy-1-oxo-(5 [α]) witha-2, 24-dienolide. a new steroidal lactone from *Withania coagulans*. *Phytochem* 1971; 10:685-688.
106. Choudhary MI, Dur-e-Shahwar, Parveen Z, Jabbar A, Ali I, Rahman AU. Ashwagandha: and its use. *Phytochem* 1995; 40:1243-1246.
107. Rahman AU, Choudhary MI, Qureshi S, Gul W, Yousaf M. Two new ergostane-type steroidal lactones from *Withania coagulans*. *J Nat Prod* 1998; 61:812-814.
108. Rahman AU, Shabbir M, Yousaf M, Qureshi S, Shahwar DE, Naz A, et al. Three withanolides from *Withania coagulans*. *Phytochem* 1999; 52:1361-1364.
109. Rahman AU, Dur-e-Shahwar NA, Choudhary MI. Withanolides from *Withania coagulans*. *Phytochem* 2003; 63:387-390.
110. Alfonso D, Bernardinelli G, Kapetanidis I. Withanolides from *Lochroma coccineum*. *Phytochem* 1993; 34:517-521.
111. Glotter E. Withanolides and related ergostane-type steroids. *Nat Prod Rep* 1991; 8:415-440.
112. Rahmatullah M, Ferdausi D, Mollik MAH, Jahan R, Chowdhury MH, Haque WM. A survey of medicinal plants used by Kaverajes of Chalna area, Khulna District, Bangladesh. *AfrJ Trad Comp Altr Med* 2010; 7:91-97.
113. Muhammad G, Hussain MA, Jantan I, Bukhari NA. *Mimosa pudica* L a high-value medicinal plant as a source of bioactives for pharmaceuticals. *Comprh Rev Food Sci Food Saf* 2016; 15:303-315.
114. Muhammad G, Hussain MA, Anwar F, Ashraf M, Gilani AH. Alhagi: a plant genus rich in bioactives for pharmaceuticals. *Phytother Res* 2015; 29:1-13.
115. Kumar A, Ali M, Rahman MS, Iqbal MA, Anand G, Kumar PN, et al. Antidote effect of plants of Himalayan sub origin against arsenic induced toxicity. *J Bio Chem Res* 2015; 2:99-109.
116. Javaid A, Shafique S, Shafique S. Management of *Parthenium hysterophorus* (Asteraceae) by *Withania somnifera* (Solanaceae). *J Nat Prod Res* 2011; 25:407-416.
117. Pant M, Ambwani T, Umapathi V. Antiviral activity of Ashwagandha extract on infectious bursal disease virus replication. *Ind J Sci Tech* 2012; 5:2750-2751.
118. Dutta UC, King G. *Materia medica of hindu*. (Calcutta, Machine press).1877.
119. Kumar S, Tewari A, Dwivedi R. The use of aphrodisiacs in medieval India. *Nagarjun* 1980; 23:170-174.
120. Sen-gupta NNK. *The Ayurvedic system of medicine* (dehli neeraaj publisiing house). II 1984.
121. Stewart L. Punjab plants comprising botanical and vernacular names and uses of most of the trees, shrubs and herbs of economic value, growing within province (Lahore, British India: the Government press) 1869.
122. Mathani BP. *Medicinal plants of western Garhwal*: khadi Gramodyog 1973; 19:269-278.
123. Girish KS, Machiah KD, Ushanandini S, Kumar HK, Nagaraju S, Govidappa M, et al. Antimicrobial properties of a non-toxic glycoprotein (WSG) from *Withania*

- somnifera (Ashwagandha). *J Basic Microbio* 2006; 46:365-374. 1522
124. Owais M, Sharad KS, Shehbaz A, Saleemuddin M. Antibacterial efficacy of *Withania somnifera* (ashwagandha) an indigenous medicinal plant against experimental murine salmonellosis. *Phytomed* 2005; 12:229-235.
125. Christina A, Joseph DG, Robert SJ, Chidambaranathan N, Ramasam M. Anticarcinogenic activity of *Withania somnifera* Dunal against Dalton's ascetic lymphoma. *J Ethnopharma* 2004; 93:359-361.
126. Dhuley JN. Effect of ashwagandha on lipid peroxidation in stress-induced animals. *J Ethnopharma* 1998; 60:173-178.
127. Ziauddin M, Phansalkar N, Patki P, Diwanay S, Patwardhan B. Studies on the immunomodulatory effects of Ashwagandha. *J Ethnopharm* 1996; 50:69-76.
128. Schliebs R, Liebmann A, Bhattacharya SK, Kumar GS, Bigl V. Systemic administration of defined extracts from *Withania somnifera* (Indian Ginseng) and Shilajit differentially affects cholinergic but not glutamatergic and GABAergic markers in rat brain. *Neurochem Int* 1997; 30:181-190.
129. Dhuley JN. Nootropic-like effect of ashwagandha (*Withania somnifera* L.) in mice. *Phytother Res* 2001; 15:524-528.
130. Panda S, Kar A. Changes in thyroid hormone concentrations after administration of ashwagandha root extract to adult male mice. *J Pharm* 1998; 50:1065-1068.
131. Panda S, Kar A. *Withania somnifera* and *Bauhinia pupurea* in the regulation of circulating thyroid hormone concentrations in female mice. *J Ethnopharm* 1999; 67:233-239.
132. Andallu B, Radhika B. Hypoglycemic, diuretic and hypocholesterolemic effect of winter cherry (*Withania somnifera*, Dunal) root. *Ind J Exp Bio* 2000; 38:607-609.
133. Javaid A, Shafique S, Shafiqu S. Herbicidal effects of extracts and residue incorporation of *Datura metel* against *Parthenium* weed. *J Nat Prod Res* 2010; 24:1426-1437.
134. Mhaskar KS, Blatter E, Caius JF. Indian medicinal plants (New Delhi, Sri satugari publications) 2000; 8:2447-2449.

HOW TO CITE: Praveen Raja S, Sri Dharshan K, Kalaivani D, Keerthana M, Overview of Bioactive Phytochemicals in *Withania somnifera* Relieving Stress and Anxiety on Cum- Huntington Disease, *Int. J. of Pharm. Sci.*, 2025, Vol 3, Issue 11, 3341-3357. <https://doi.org/10.5281/zenodo.17672594>